Lake Street Maintains Avita Medical(RCEL.US) With Buy Rating, Cuts Target Price to $20
AVITA Medical Analyst Ratings
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Maintains Target Price $15
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Maintains Target Price $15
Avita Medical: Strong Buy Rating Backed by Record Sales and Promising Growth Prospects
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Maintains Target Price $15
AVITA Medical Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on AVITA Medical, Maintains $21 Price Target
Lake Street Issues a Buy Rating on Avita Medical (RCEL)
BTIG Remains a Hold on Avita Medical (RCEL)
Avita Medical Maintains Buy Rating Amid Strong Quarterly Performance and Positive Growth Outlook
Lake Street Maintains Avita Medical(RCEL.US) With Buy Rating, Maintains Target Price $40
Avita Medical (RCEL) Gets a Buy From Lake Street
BTIG Keeps Their Hold Rating on Avita Medical (RCEL)
Lake Street Sticks to Their Buy Rating for Avita Medical (RCEL)
Buy Rating Affirmed: Avita Medical's Strategic Wins Promise Growth and Market Penetration
AVITA Downgraded by Piper Sandler Over Sales Outlook
Piper Sandler: The AVITA Medical (RCEL.US) rating was lowered from an increase in holdings to a neutral rating, and the target price was adjusted from $21.00 to $9.00.
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL), Inotiv (NOTV) and Hims & Hers Health (HIMS)
AVITA Medical Analyst Ratings